Avalo Therapeutics AVTX
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$1.46M (10 inflow days, 10 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 36.2% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 24.41% to 16.62% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Trails Edge Capital Partners, LP | Hedge Fund | 2026/Q3 | +1,911,880 | 4.8% |
| BlackRock | Mutual Fund | 2026/Q3 | +594,051 | 8.6% |
| BlackRock | Mutual Fund | 2026/Q3 | +4,038,471 | 8.1% |
| Deep Track Capital, LP | VC/PE Fund | 2026/Q3 | +3,610,000 | 6.2% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +2,817,633 | 5.4% |
| TCG Crossover Management, LLC | VC/PE Fund | 2026/Q3 | +2,278,737 | 5.2% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q3 | +1,782,926 | 4.8% |
| Braidwell LP | Hedge Fund | 2026/Q3 | +1,629,182 | 2.8% |
| Farallon Capital Management, L.L.C. | Hedge Fund | 2026/Q3 | +1,582,000 | 4.3% |
| Affinity Asset Advisors, LLC | Hedge Fund | 2026/Q3 | +1,559,160 | 5.0% |
| Caligan Partners, LP | Hedge Fund | 2026/Q3 | +1,528,843 | 5.5% |
| Point72 Asset Management, L.P. | Hedge Fund | 2026/Q3 | +1,470,884 | 4.1% |
| Bank of America Corporation | Public Company | 2026/Q3 | +1,270,829 | 3.3% |
| AllianceBernstein | Mutual Fund | 2026/Q3 | +1,260,689 | 2.4% |
| Soleus Capital Management, L.P. | Hedge Fund | 2026/Q3 | +1,213,000 | 2.9% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 29 Sep 2026 | Kevin Lind | Independent Director | Other Derivative Acquisition | +1,352 | $15.33 | 1,352 |
| 29 Sep 2026 | Rita Jain | Independent Director | Other Derivative Acquisition | +1,322 | $15.33 | 1,322 |
| 29 Sep 2026 | Ron Philip | Independent Director | Other Derivative Acquisition | +1,109 | $15.33 | 1,109 |
| 15 Sep 2026 | Christopher Sullivan | CFO & Head of Investor relations | Derivative Exercise and Sale | -12,394 | $16.33 | 39,900 |
| 9 Sep 2026 | Christopher Sullivan | CFO & Head of Investor relations | Derivative Exercise and Sale | -10,185 | $17.62 | 39,900 |
| 27 Aug 2026 | Mittie Doyle | Chief Medical Officer | Derivative Exercise and Sale | -679 | $20.00 | 8,276 |
| 17 Aug 2026 | Christopher Sullivan | CFO & Head of Investor relations | Derivative Exercise and Sale | -71,852 | $20.05 | – |
| 16 Aug 2026 | Mittie Doyle | Chief Medical Officer | Derivative Exercise and Sale | -1,000 | $20.00 | 8,276 |
| 16 Aug 2026 | Christopher Sullivan | CFO & Head of Investor relations | Open Market Disposition | -873 | $19.94 | – |
| 10 Aug 2026 | Jennifer Riley | Chief Strategy Officer | Open Market Disposition | -2,655 | $19.59 | 2,841 |
| 9 Aug 2026 | Mittie Doyle | Chief Medical Officer | Derivative Exercise and Sale | -679 | $20.00 | 8,276 |
| 26 Jul 2026 | Mittie Doyle | Chief Medical Officer | Derivative Exercise and Sale | -1,000 | $20.00 | 8,276 |
| 29 Jun 2026 | Kevin Lind | Independent Director | Other Derivative Acquisition | +1,105 | $18.48 | 1,105 |
| 29 Jun 2026 | Mittie Doyle | Chief Medical Officer | Derivative Exercise and Sale | -4,654 | $20.00 | 8,276 |
| 29 Jun 2026 | Rita Jain | Independent Director | Other Derivative Acquisition | +1,080 | $18.48 | 1,080 |
| 29 Jun 2026 | Ron Philip | Independent Director | Other Derivative Acquisition | +69 | $18.48 | 69 |
| 22 Jun 2026 | Mittie Doyle | Chief Medical Officer | Derivative Exercise and Sale | -1,450 | $18.00 | 8,276 |
| 22 Jun 2026 | Ron Philip | Independent Director | Other Derivative Acquisition | +40,200 | $17.83 | 40,200 |
| 9 Jun 2026 | Mittie Doyle | Chief Medical Officer | Sale to Issuer | -1,084 | $13.10 | 8,276 |
| 9 Jun 2026 | Paul Varki | Chief Legal Officer | Sale to Issuer | -1,081 | $13.10 | 8,276 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 8,910,655 | 16.6% | 2.1 |
| 15 Oct 2026 | 11,963,625 | 22.3% | 13.0 |
| 30 Sep 2026 | 11,405,304 | 21.3% | 8.8 |
| 15 Sep 2026 | 12,925,869 | 24.1% | 13.2 |
| 31 Aug 2026 | 12,387,012 | 23.1% | 15.2 |
| 14 Aug 2026 | 13,092,767 | 24.4% | 20.2 |
No comments yet — be the first to weigh in on AVTX.
Sign in to join the discussion.